[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571464":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":69,"collaborators":23,"id":72,"slug":23,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":23,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":23,"enrollmentInfo":80,"targetDuration":23,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":50,"whyStopped":23,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"PDE5 Inhibitor Therapy in Men with Vasculogenic Erectile Dysfunction (ED)","ACTIVE_COMPARATOR","Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: Daily low-dose PDE5 inhibitor therapy. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.",[13],"Drug: Daily low-dose PDE5 inhibitor therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Testosterone Therapy in Hypogonadal Men","Population: 40 hypogonadal men aged 18 or above Intervention: Testosterone therapy as per clinical guidelines. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.",[18],"Drug: Testosterone therapy as per clinical guidelines.",{"label":20,"type":21,"description":22,"interventionNames":23},"Vasculogenic ED confirmed by penile Doppler ultrasound","NO_INTERVENTION","Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: None Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.",null,[25,30],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":23},"DRUG","Daily low-dose PDE5 inhibitor therapy","Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention in each arm.",[9],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":23},"Testosterone therapy as per clinical guidelines.","Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention.",[15],[35],{"name":36,"affiliation":5,"role":37},"Faysal A Yafi, MD","PRINCIPAL_INVESTIGATOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":23,"email":43},"Muhammed AM Hammad, MBBCh","CONTACT","714-456-7005","mahammad@hs.uci.edu",{"name":45,"role":41,"phone":42,"phoneExt":23,"email":46},"Elia Abou Chawareb, MD","eaboucha@hotmail.com",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"UCI Urology | Men's Health Center","RECRUITING","Newport Beach","California","92660","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-117.92895,33.61891,{"lat":60,"lon":59},[63,66,68],{"name":64,"role":41,"phone":65,"phoneExt":23,"email":43},"Muhammed AM Hammad, Mbbch","7144567005",{"name":45,"role":41,"phone":65,"phoneExt":23,"email":67},"eaboucha@hs.uci.edu",{"name":36,"role":37,"phone":23,"phoneExt":23,"email":23},{"type":37,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Faysal Yafi","Associate Professor of Urology Director of Men's Health and Newport Urology Chief, Division of Men's Health and Reconstructive Urology","100571464",false,"NCT06720597","EndoPAT Device for Endothelial Dysfunction in ED","Utilizing EndoPAT Device for Endothelial Dysfunction Assessment in Erectile Dysfunction and Hormonal Therapy","Inclusion Criteria:\n\n* Males 18 years old and above\n* Diagnosed with erectile dysfunction or hypogonadism\n\nExclusion Criteria:\n\n* Patients without the above criteria","MALE","18 Years",{"count":81,"type":82},120,"ESTIMATED","INTERVENTIONAL",[85],"NA","To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound.\n\nTo evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy.\n\nTo investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy",[88,89,90],"Erectile Dysfunction","Hypogonadism, Male","Endothelial Dysfunction",[92,88,93,90,94,95],"EndoPAT","Hypogonadism","ED","Testosterone","2026-01-29",{"date":98,"type":99},"2026-02-02","ACTUAL",{"date":101,"type":99},"2025-08-13",{"date":103,"type":82},"2027-01",{"name":5,"class":6},1]